Navigation Links
PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity
Date:7/15/2010

ccine formulation may be able to provide protection against anthrax infection with fewer doses than a liquid vaccine formulation.  We will be conducting additional studies to confirm these preliminary results.  In addition, a lyophilized formulation could yield important practical advantages in the field."

Previously, the Company announced that its lyophilized rPA vaccine candidate was structurally stable and potent at various temperatures up to and including 70 degrees Celsius.  One of the goals of PharmAthene's rPA program is to develop a stable cold-chain-free vaccine, which could be stored and distributed at room temperature -- an important advantage for deployment in the civilian Strategic National Stockpile.

The Institute of Medicine has declared an urgent need to develop and stockpile next generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience, cost-effectiveness, and more rapid immunity.   PharmAthene is committed to working with its partners in the United States government to address this need.

Funding for the lyophilized rPA vaccine program was provided under a Challenge grant (UC1 AI067223) from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and gastrointestinal ant
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
2. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
3. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
5. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
6. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
7. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
8. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
10. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
11. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Reportlinker.com announces ... is available in its catalogue: ... Services Industry (U.S.): Analytics, Extensive Financial ... 2021, NAIC 541380 ... Testing Laboratories, Safety and Compliance Services ...
(Date:8/28/2014)... 2014 Reportlinker.com announces that a new ... North America Laparoscopes Market Outlook to ... North America Laparoscopes Market Outlook to 2020 ... Laparoscopes Market Outlook to 2020", provides key market ... report provides value, in millions of US dollars, ...
(Date:8/28/2014)... DALLAS , Aug. 28, 2014 /PRNewswire-iReach/ -- ... Poland (Photo - ... " CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Poland ... identifies key trends in the healthcare market and ... and healthcare infrastructure. Most importantly, the report provides ...
Breaking Medicine Technology:Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6North America Laparoscopes Market Outlook to 2020 2North America Laparoscopes Market Outlook to 2020 3North America Laparoscopes Market Outlook to 2020 4North America Laparoscopes Market Outlook to 2020 5North America Laparoscopes Market Outlook to 2020 6North America Laparoscopes Market Outlook to 2020 7North America Laparoscopes Market Outlook to 2020 8North America Laparoscopes Market Outlook to 2020 9North America Laparoscopes Market Outlook to 2020 10North America Laparoscopes Market Outlook to 2020 11Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5
... Jan. 11 Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: ... in San Francisco. The conference will be held January 11-14, 2010, at ... 2010, 2:00 PM Pacific Time. The conference will be webcast live with ... accessed at www.celltherapeutics.com . , , ...
... , DURHAM, N.C., Jan. 8 Oxygen Biotherapeutics, ... stock has been approved for listing on the NASDAQ Capital ... the NASDAQ is a very important milestone for our company," ... on the NASDAQ provides us with greater visibility for our ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) to Present at the 28th Annual JP Morgan Healthcare Conference 2Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing 2
(Date:8/28/2014)... Blood's Thicker Than Water is based on a true ... the heart of the city. Raymond E. Blake paints this ... disrespect caused two families to collide with each other and ... Boyz and the M.O.B. Boyz clash in a rain of ... a silent terror. "Guerrilla," AKA "Real," runs his Mob family ...
(Date:8/28/2014)... August 28, 2014 Millennium Treatment Group recently ... is extremely large, and Millennium Treatment Group is working to ... that they need. , According to the National Survey ... 21 million Americans could have benefited from treatment for drug ... received help. This means that there is a large treatment ...
(Date:8/28/2014)... Lake Worth, FL (PRWEB) August 28, 2014 ... of drug use affecting users in the workplace. A ... and Drug Dependence (NCADD) states that drug abuse ... , Employees who use or are addicted to drugs ... Drug users’ activities carry over into the workplace, causing ...
(Date:8/28/2014)... 28, 2014 (HealthDay News) -- Arguments between parents may ... indicates. Parents in more than 200 families were ... At the end of each day, mothers and fathers ... with their children. On days when parents reported ... their children were also strained, according to the study ...
(Date:8/28/2014)... As the federal government plans its exit strategy from ... rethink its role in providing health care to veterans, says ... Medicine . , "To simply go on doing more of ... the Veterans Health Administration,s cost and population structure pose in ... for Health Policy & Clinical Practice, and David Auerbach, from ...
Breaking Medicine News(10 mins):Health News:Raymond E. Blake Releases Blood's Thicker Than Water, Based on a True Story 2Health News:Millennium Treatment Group Works to Close Treatment Gap 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Parents' Fights May Strain Bonds With Their Kids 2Health News:A VA exit strategy 2
... may extend life for those with tumors in bile duct, ... a second chemotherapy drug to the treatment regimen of people ... to new research. , This type of cancer -- which ... notoriously difficult to treat and often fatal. , "These ...
... ... fat deposits and reshapes the body. Clinically proven, the maximus system powered by TriLipo, ... inch-loss, cellulite reduction and lax skin tightening. , ... Tel Aviv, Israel (PRWEB) April 7, 2010 - ...
... Researchers from Boston University School of Medicine (BUSM) ... have discovered a new approach for identifying smokers at ... which appear in the April 7th issue of ... use a genomic approach to prevent lung cancer in ...
... Ford Hospital have found that infection with the hepatitis ... Using administrative data from more than 67,000 Henry ... period 1997-2008, 0.6% (17/3057) patients with hepatitis C infection ... the disease developed kidney cancer. After controlling ...
... American guts don,t, study finds, , WEDNESDAY, April 7 ... human intestinal tract that help everything from digesting food ... culture because of variations in diet, researchers now report. ... microbiology by researchers in France, who identified genes in ...
... Cancer cells grow so fast that they can outstrip their ... produce energy in a way that needs less oxygen but ... Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove ... that sugar supply, causing the cells to self destruct. ...
Cached Medicine News:Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 2Health News:Progress Made Against Tough-to-Treat Biliary Tract Cancers 3Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 2Health News:Pollogen Launches the Maximus, Advanced Solution for Fat Reduction and Body Shaping based on Innovative TriLipo Technology 3Health News:Researchers discover new approach for identifying smokers at highest risk for developing lung cancer 2Health News:Henry Ford Hospital atudy: Hepatitis C infection doubles risk for kidney cancer 2Health News:You Are What Microbes You Eat 2Health News:You Are What Microbes You Eat 3Health News:New agent chokes off energy supply, kills cancer cells 2
... CO2 system was expressly designed to obtain ... A special source and an equally special ... create particular high energy impulses with constant ... as 'top-flat shaped') allow storage of enough ...
... PhotoLight is an exceptional condensate ... functional dimensions for ensuring a ... a constantly evolving professional market. ... working in different studios who ...
... the result of DEKA s new ... three different methods capable of restoring ... This treatment is designed to dramatically ... the combined action of a localized ...
... combines its great versatility in epilation ... with the compactness and easy-transportability of ... vascular protocols developed for Smartepil II ... is indicated for hair removal of ...
Medicine Products: